SPECIALTY TOPICS · GUIDE
Digital CBT for Insomnia (CBT-I): Evidence
What research shows about CBT for insomnia delivered by app or website, how it compares with a therapist, the two cleared products, and who should check with a clinician first.
Content last updated . This page has not been medically reviewed.
Back to Emerging Wellness ScienceWhy CBT-I is the reference point
The American College of Physicians recommended CBT-I as the initial treatment for chronic insomnia disorder in adults (strong recommendation, moderate-quality evidence). [1] The American Academy of Sleep Medicine's 2021 guideline strongly recommended multicomponent CBT-I and suggested against sleep hygiene alone as a single treatment. [2] The NHS says CBT may be face-to-face with a therapist or through an online self-help program. [3] These guidelines are about CBT-I in general; the digital versions have to earn their own evidence. See also CBT for Insomnia in our Wellness section.What research shows about the digital version
- Fully automated programs. A 2025 meta-analysis of 29 randomized trials with 9,475 participants found moderate to large effects on insomnia severity compared with controls, but less effect than therapist-assisted CBT-I. It concluded that adherence mattered, and that a hybrid with therapist support was more beneficial. [4]
- Internet-delivered programs. A 2016 meta-analysis of 15 trials found sleep efficiency improved by 7.2 percentage points and Insomnia Severity Index scores fell 4.3 points versus control, with benefits maintained from 4 to 48 weeks, and no statistically significant difference from in-person therapy on the main measures. [5]
- Daytime outcomes. A trial of 1,711 adults compared a web and mobile digital CBT program with online sleep hygiene education. The digital program gave small gains in functional health and well-being and a large improvement in sleep-related quality of life, at 24 weeks. [6]
Label: established for adults with insomnia symptoms using programs built on CBT-I, with moderate to large average effects; mixed on how it compares with therapist-led care. Not every app has been tested; results come from specific programs. See Product-Specific Trials for Digital Health.
Cleared products (United States and United Kingdom)
| Product | Regulator and record | Indication as read |
|---|---|---|
| Somryst | FDA 510(k) K191716, March 23, 2020 [7] | Prescription-only CBT-I for chronic insomnia, patients 22 and older [8] |
| Sleepio | FDA 510(k) K233577, letter August 5, 2024 [9] | Prescription device delivering CBT-I for chronic insomnia or insomnia disorder, adjunct to usual care, patients 18 and older [9] |
In the United Kingdom, NICE recommended Sleepio (published May 20, 2022) as a cost saving option for insomnia in primary care for people who would otherwise be offered sleep hygiene or sleeping pills. NICE also said there is no direct evidence of its effectiveness compared with face-to-face CBT-I. [10] These are product-specific records. They do not apply to other sleep apps. See Wellness Apps vs Digital Therapeutics.
Related
Sleep trackers do not deliver CBT-I and have their own accuracy limits: Sleep Trackers and Sleep Testing.Frequently asked questions
Is digital CBT-I as good as seeing a therapist?
Reviews suggest it is effective, but fully automated programs showed less effect than therapist-assisted CBT-I. [4] An earlier meta-analysis found no significant difference from in-person therapy on main sleep measures. [5] NICE noted the lack of direct comparison for Sleepio. [10]
Do I need a prescription?
The two FDA-cleared products above are prescription devices. [8][9] Other CBT-I programs sold to the public may be sold as wellness products; whether they have trial evidence varies.
Will it work quickly?
The 24-week trial results suggest benefits built over weeks, not overnight. [6] Participants had up to 12 weeks to complete the programs. [6]
Is it safe?
No adverse or serious adverse events were reported in the trial summarized in the Sleepio FDA record. [9] That was one trial. People with other sleep disorders should be assessed first. [10]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Limits of the evidence
- Who was studied. In the 1,711-person trial, 77.7% were female and 91.1% were white, so results may not apply equally to everyone. [6]
- Self-reported outcomes. Most studies measure sleep with questionnaires and diaries, not lab sleep tests.
- Heterogeneity and funding. The programs vary, some studied products are commercial, and we did not verify the funding of every trial. See Conflicts of Interest and Funding in Research.
- Adherence. The 2025 analysis found completion rate did not moderate outcomes, but adherence did. [4]
Who should check with a clinician first
- Possible other sleep disorders. NICE says people who may be at higher risk of other sleep disorders, such as in pregnancy or with other health conditions, should have a medical assessment before referral to Sleepio. [10] Loud snoring, gasping at night or heavy daytime sleepiness are reasons to ask about sleep apnea.
- Insomnia with depression, anxiety or other conditions. Ask your clinician how digital CBT-I fits with your care.
- Children and teens. The cleared products above are indicated for adults. [9]
Ask your clinician before starting if you have another medical or mental health condition. For when to seek care, see Sleep Safety and When to Get Help.
References
- Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 2016. Read 2026-10-22.
- Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 2021. Read 2026-10-22.
- NHS (UK). Insomnia: treatment. Page last reviewed 19 March 2024. Read 2026-10-22.
- Systematic review and meta-analysis on fully automated digital cognitive behavioral therapy for insomnia. npj Digital Medicine, 2025. Read 2026-10-22.
- Internet-delivered cognitive behavioral therapy to treat insomnia: a systematic review and meta-analysis. PLoS One, 2016. Read 2026-10-22.
- Effect of digital cognitive behavioral therapy for insomnia on health, psychological well-being, and sleep-related quality of life: a randomized clinical trial. JAMA Psychiatry, 2019. Read 2026-10-22.
- U.S. Food and Drug Administration. 510(k) Premarket Notification database record K191716 (Somryst). Read 2026-10-22.
- U.S. Food and Drug Administration. Somryst 510(k) K191716: clearance letter, indications for use and summary. Read 2026-10-22.
- U.S. Food and Drug Administration. Sleepio 510(k) K233577: clearance letter and summary. Read 2026-10-22.
- National Institute for Health and Care Excellence (UK). Sleepio to treat insomnia and insomnia symptoms (HealthTech guidance HTG624, formerly MTG70). Read 2026-10-22.